MX2020001170A - Compuestos biciclicos de pirazol y triazolo como inhibidores de las cinasas jak. - Google Patents
Compuestos biciclicos de pirazol y triazolo como inhibidores de las cinasas jak.Info
- Publication number
- MX2020001170A MX2020001170A MX2020001170A MX2020001170A MX2020001170A MX 2020001170 A MX2020001170 A MX 2020001170A MX 2020001170 A MX2020001170 A MX 2020001170A MX 2020001170 A MX2020001170 A MX 2020001170A MX 2020001170 A MX2020001170 A MX 2020001170A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- pyrazolo
- kinase inhibitors
- jak kinase
- bicyclic compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La invención proporciona compuestos de la fórmula (I): (ver Fórmula) o una sal farmacéuticamente aceptable de este, donde las variables se definen en la especificación, que son inhibidores de quinasas JAK, particularmente JAK3. La invención también proporciona formas cristalinas, composiciones farmacéuticas que comprenden tales compuestos, métodos para usar dichos compuestos para tratar enfermedades inflamatorias de tipo gastrointestinales y de otro tipo, y procesos y productos intermedios útiles para preparar tales compuestos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762539642P | 2017-08-01 | 2017-08-01 | |
PCT/US2018/044508 WO2019027960A1 (en) | 2017-08-01 | 2018-07-31 | BICYCLIC PYRAZOLO AND TRIAZOLO COMPOUNDS AS JAK KINASE INHIBITORS |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020001170A true MX2020001170A (es) | 2020-03-12 |
Family
ID=63209687
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020001170A MX2020001170A (es) | 2017-08-01 | 2018-07-31 | Compuestos biciclicos de pirazol y triazolo como inhibidores de las cinasas jak. |
Country Status (23)
Country | Link |
---|---|
US (4) | US10392368B2 (es) |
EP (1) | EP3652169A1 (es) |
JP (2) | JP7098716B2 (es) |
KR (1) | KR20200036004A (es) |
CN (1) | CN111032646B (es) |
AR (1) | AR112348A1 (es) |
AU (1) | AU2018312349A1 (es) |
BR (1) | BR112020002265A2 (es) |
CA (1) | CA3069990A1 (es) |
CL (1) | CL2020000283A1 (es) |
CO (1) | CO2020001469A2 (es) |
EA (1) | EA038912B1 (es) |
IL (1) | IL272031A (es) |
MA (1) | MA49570A (es) |
MX (1) | MX2020001170A (es) |
MY (1) | MY200629A (es) |
PE (1) | PE20201028A1 (es) |
PH (1) | PH12020500201A1 (es) |
SG (1) | SG11202000602YA (es) |
TW (1) | TW201920150A (es) |
UA (1) | UA125318C2 (es) |
WO (1) | WO2019027960A1 (es) |
ZA (1) | ZA202000561B (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112020002265A2 (pt) | 2017-08-01 | 2020-07-28 | Theravance Biopharma R&D Ip, Llc | compostos pirazólicos e triazólicos bicíclicos como inibidores de jak quiinase |
CN113498352A (zh) | 2019-01-23 | 2021-10-12 | 施万生物制药研发Ip有限责任公司 | 作为jak抑制剂的咪唑并[1,5-a]吡啶、1,2,4-***并[4,3-a]吡啶和咪唑并[1,5-a]吡嗪 |
WO2021231272A1 (en) * | 2020-05-14 | 2021-11-18 | Theravance Biopharma R&D Ip, Llc | Administration of gut-selective jak3 inhibitor |
US20230339977A1 (en) * | 2020-08-13 | 2023-10-26 | Sunshine Lake Pharma Co., Ltd. | Substituted heteroaryl compound, and composition and application thereof |
CN114075220A (zh) * | 2020-08-13 | 2022-02-22 | 广东东阳光药业有限公司 | 取代的杂芳基化合物及其组合物和用途 |
CN116157388A (zh) * | 2020-09-10 | 2023-05-23 | 四川海思科制药有限公司 | 一种碳环酰胺衍生物及其在医药上的应用 |
WO2022199599A1 (zh) * | 2021-03-23 | 2022-09-29 | 凯复(苏州)生物医药有限公司 | 丙烯酰基取代的化合物、包含其的药物组合物及其用途 |
JP2024514090A (ja) * | 2021-03-29 | 2024-03-28 | ブリストル-マイヤーズ スクイブ カンパニー | 6-(シクロプロパンカルボキサミド)-4-((2-メトキシ-3-(1-メチル-1h-1,2,4-トリアゾール-3-イル)フェニル)アミノ)-n-(メチル-d3)ピリダジン-3-カルボキサミドの結晶形態 |
CN113061137B (zh) * | 2021-04-02 | 2022-08-02 | 广西医科大学 | 含氮杂环衍生物或其药学上可接受的盐和用途 |
MX2023013052A (es) * | 2021-05-03 | 2024-01-12 | Incyte Corp | Inhibidores de la via de la cinasa jano 1 (jak1) para el tratamiento del prurigo nodularis. |
CN116332961A (zh) * | 2021-12-23 | 2023-06-27 | 广东东阳光药业有限公司 | 取代的杂芳基化合物及其组合物和用途 |
WO2023165562A1 (zh) * | 2022-03-02 | 2023-09-07 | 南京明德新药研发有限公司 | 含氮杂环类化合物及其应用 |
GB202213163D0 (en) | 2022-09-08 | 2022-10-26 | Cambridge Entpr Ltd | Novel compounds, compositions and therapeutic uses thereof |
GB202213164D0 (en) | 2022-09-08 | 2022-10-26 | Cambridge Entpr Ltd | Novel compounds, compositions and therapeutic uses thereof |
Family Cites Families (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR034588A1 (es) | 2001-04-20 | 2004-03-03 | Wyeth Corp | Derivados heterociclilalcoxi-, -alquiltio- y -alquilamino-benzazol como ligandos de 5-hidroxitriptamina-6, un proceso para su preparacion, intermediarios, composiciones farmaceuticas y el uso de dichos derivados para la manufactura de medicamentos |
FR2836915B1 (fr) | 2002-03-11 | 2008-01-11 | Aventis Pharma Sa | Derives d'aminoindazoles, procede de preparation et intermediaires de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant |
US20030139427A1 (en) | 2002-08-23 | 2003-07-24 | Osi Pharmaceuticals Inc. | Bicyclic pyrimidinyl derivatives and methods of use thereof |
JP4810427B2 (ja) | 2003-05-22 | 2011-11-09 | アボット・ラボラトリーズ | インダゾール、ベンズイソオキサゾールおよびベンズイソチアゾールキナーゼ阻害剤 |
EP1647549A1 (en) | 2004-10-14 | 2006-04-19 | Laboratoire Theramex | Indazoles, benzisoxazoles and benzisothiazoles as estrogenic agents |
CA2626579A1 (en) | 2005-10-25 | 2007-05-03 | Abbott Laboratories | Formulation comprising a drug of low water solubility and method of use thereof |
WO2007117995A2 (en) | 2006-03-30 | 2007-10-18 | Takeda San Diego, Inc. | Kinase inhibitors |
KR100834758B1 (ko) | 2006-07-05 | 2008-06-05 | 삼성전자주식회사 | 컴퓨터 시스템 보안 장치 및 방법 |
JP2009007342A (ja) | 2007-06-01 | 2009-01-15 | Mitsubishi Tanabe Pharma Corp | 医薬組成物 |
US8648069B2 (en) | 2007-06-08 | 2014-02-11 | Abbvie Inc. | 5-substituted indazoles as kinase inhibitors |
ES2383246T3 (es) | 2008-06-05 | 2012-06-19 | Glaxo Group Limited | 4-amino-indazoles |
EP2280705B1 (en) | 2008-06-05 | 2014-10-08 | Glaxo Group Limited | Novel compounds |
EP2300437B1 (en) | 2008-06-05 | 2013-11-20 | Glaxo Group Limited | Benzpyrazol derivatives as inhibitors of pi3 kinases |
EP2322520A4 (en) | 2008-07-28 | 2012-04-25 | Jiangsu Guohua Invest Co Ltd | ARALKYL-SUBSTITUTED PIPERIDINE OR PIPERAZINE DERIVATIVES AND USES THEREOF FOR THE TREATMENT OF SCHIZOPHRENIA |
TW201111385A (en) | 2009-08-27 | 2011-04-01 | Biocryst Pharm Inc | Heterocyclic compounds as janus kinase inhibitors |
FR2951172B1 (fr) | 2009-10-13 | 2014-09-26 | Pf Medicament | Derives pyrazolopyridines en tant qu'agent anticancereux |
JP2013512878A (ja) | 2009-12-03 | 2013-04-18 | グラクソ グループ リミテッド | 新規化合物 |
EP2507223A1 (en) | 2009-12-03 | 2012-10-10 | Glaxo Group Limited | Benzpyrazole derivatives as inhibitors of p13 kinases |
TW201200518A (en) | 2010-03-10 | 2012-01-01 | Kalypsys Inc | Heterocyclic inhibitors of histamine receptors for the treatment of disease |
DK2635299T3 (da) | 2010-11-02 | 2019-10-21 | Univ Columbia | Fremgangsmåder til behandling af hårtabsforstyrrelser |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
US8846712B2 (en) | 2011-09-12 | 2014-09-30 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
CN102993201A (zh) * | 2011-09-14 | 2013-03-27 | 赛诺菲 | 作为激酶抑制剂的6-(4-羟基-苯基)-3-苯乙烯基-1H-吡唑并[3,4-b]吡啶-4-羧酸酰胺衍生物 |
EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
US20130102601A1 (en) | 2011-10-21 | 2013-04-25 | F. Hoffmann-La Roche Ltd | Pyrimidin-4-one derivatives and their use in the treatment, amelioration or prevention of a viral disease |
EP2771340B1 (en) | 2011-10-25 | 2016-04-13 | Sanofi | 6-(4-hydroxy-phenyl)-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013085802A1 (en) * | 2011-12-06 | 2013-06-13 | Merck Sharp & Dohme Corp. | Pyrrolopyrimidines as janus kinase inhibitors |
US8377946B1 (en) * | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
SI2830662T1 (sl) | 2012-03-29 | 2019-01-31 | The Trustees Of Columbia University In The City Of New York | Postopki zdravljenja motenj izgube las |
EP2847191B1 (en) * | 2012-05-09 | 2016-06-15 | Sanofi | Substituted 6-(4-hydroxy-phenyl)-1h-pyrazolo[3,4-b]pyridine derivatives as kinase inhibitors |
TWI629275B (zh) | 2013-03-13 | 2018-07-11 | 賽諾菲公司 | N-(4-(氮雜吲唑-6-基)-苯基)-磺醯胺及其作為醫藥之用途 |
JP2016113366A (ja) * | 2013-03-29 | 2016-06-23 | 大鵬薬品工業株式会社 | アセトアミド基を有する1,2,4−トリアジン−6−カルボキサミド誘導体 |
CN107417684A (zh) | 2013-12-05 | 2017-12-01 | 辉瑞公司 | 杂环丙烯酰胺 |
US20160376240A1 (en) | 2014-01-24 | 2016-12-29 | Abbvie Inc. | 6 Phenyl or 6 Pyridin 3 YL Indazole Derivatives and Methods of Use |
ES2921874T3 (es) * | 2014-02-28 | 2022-09-01 | Nimbus Lakshmi Inc | Inhibidores de TYK2 y usos de los mismos |
MX2016014878A (es) | 2014-05-14 | 2017-03-08 | Pfizer | Pirazolopiridinas y pirazolopirimidinas. |
WO2016011394A1 (en) | 2014-07-18 | 2016-01-21 | The General Hospital Corporation | Imaging agents for neural flux |
EP3215156A2 (en) | 2014-11-03 | 2017-09-13 | Iomet Pharma Ltd. | Pharmaceutical compound |
CN105837574B (zh) | 2015-02-02 | 2018-03-02 | 四川大学 | N‑(3‑哌啶基)‑芳香胺衍生物及其制备方法和用途 |
ES2928757T3 (es) | 2015-05-01 | 2022-11-22 | Pfizer | Acrilamidas de pirrolo[2,3-b]pirazinilo y epóxidos de las mismas como inhibidores de la Janus Quinasa |
AU2016259023A1 (en) | 2015-05-07 | 2017-11-30 | The Trustees Of Columbia University In The City Of New York | Methods and compositions for promoting hair growth |
PT3712152T (pt) | 2015-11-03 | 2021-04-15 | Topivert Pharma Ltd | Derivados de 4,5,6,7-tetrahidro-1h-imidazo[4,5-c]piridina e 1,4,5,6,7,8-hexahidroimidazo[4,5-d]azepina como inibidores de janus quinase |
JP7096592B2 (ja) | 2016-02-16 | 2022-07-06 | ワシントン・ユニバーシティ | Jak阻害剤およびこれらの利用 |
EP3950691A1 (en) | 2016-06-30 | 2022-02-09 | Daewoong Pharmaceutical Co., Ltd. | Pyrazolopyrimidine derivatives as kinase inhibitor |
WO2018049174A1 (en) | 2016-09-08 | 2018-03-15 | Synergistic Therapeutics, Llc | Topical hair growth formulation |
WO2018075937A1 (en) | 2016-10-21 | 2018-04-26 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors and uses thereof |
US20180117148A1 (en) | 2016-10-28 | 2018-05-03 | Andrew J. Holman | Compounds, pharmaceutical compositions and methods of treatments of immune related diseases and disorders |
KR102032418B1 (ko) * | 2017-06-15 | 2019-10-16 | 한국화학연구원 | 접합 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 브루톤티로신 키나제 활성 관련 질환의 예방 또는 치료용 약학적 조성물 |
BR112020002265A2 (pt) | 2017-08-01 | 2020-07-28 | Theravance Biopharma R&D Ip, Llc | compostos pirazólicos e triazólicos bicíclicos como inibidores de jak quiinase |
CA3081751A1 (en) | 2017-11-03 | 2019-05-09 | Aclaris Therapeutics, Inc. | Substituted pyrrolopyrimidine jak inhibitors and methods of making and using the same |
RU2758370C1 (ru) | 2017-12-28 | 2021-10-28 | Даевунг Фармасьютикал Ко., Лтд. | Производные оксифторпиперидина в качестве ингибитора киназы |
KR102577241B1 (ko) | 2017-12-28 | 2023-09-11 | 주식회사 대웅제약 | 카이네이즈 저해제로서의 아미노-플루오로피페리딘 유도체 |
KR102577242B1 (ko) | 2017-12-28 | 2023-09-11 | 주식회사 대웅제약 | 카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체 |
CN113498352A (zh) * | 2019-01-23 | 2021-10-12 | 施万生物制药研发Ip有限责任公司 | 作为jak抑制剂的咪唑并[1,5-a]吡啶、1,2,4-***并[4,3-a]吡啶和咪唑并[1,5-a]吡嗪 |
WO2021231272A1 (en) * | 2020-05-14 | 2021-11-18 | Theravance Biopharma R&D Ip, Llc | Administration of gut-selective jak3 inhibitor |
-
2018
- 2018-07-31 BR BR112020002265-9A patent/BR112020002265A2/pt not_active Application Discontinuation
- 2018-07-31 WO PCT/US2018/044508 patent/WO2019027960A1/en unknown
- 2018-07-31 CN CN201880050675.3A patent/CN111032646B/zh active Active
- 2018-07-31 MX MX2020001170A patent/MX2020001170A/es unknown
- 2018-07-31 US US16/050,227 patent/US10392368B2/en active Active
- 2018-07-31 SG SG11202000602YA patent/SG11202000602YA/en unknown
- 2018-07-31 EA EA202090413A patent/EA038912B1/ru unknown
- 2018-07-31 CA CA3069990A patent/CA3069990A1/en not_active Abandoned
- 2018-07-31 MA MA049570A patent/MA49570A/fr unknown
- 2018-07-31 AU AU2018312349A patent/AU2018312349A1/en not_active Abandoned
- 2018-07-31 EP EP18755621.2A patent/EP3652169A1/en not_active Withdrawn
- 2018-07-31 UA UAA202001352A patent/UA125318C2/uk unknown
- 2018-07-31 KR KR1020207005956A patent/KR20200036004A/ko not_active Application Discontinuation
- 2018-07-31 MY MYPI2020000251A patent/MY200629A/en unknown
- 2018-07-31 JP JP2020505224A patent/JP7098716B2/ja active Active
- 2018-07-31 PE PE2020000171A patent/PE20201028A1/es unknown
- 2018-07-31 AR ARP180102151 patent/AR112348A1/es unknown
- 2018-07-31 TW TW107126579A patent/TW201920150A/zh unknown
-
2019
- 2019-06-28 US US16/456,179 patent/US10538513B2/en active Active
- 2019-11-19 US US16/688,109 patent/US10968205B2/en active Active
-
2020
- 2020-01-14 IL IL272031A patent/IL272031A/en unknown
- 2020-01-27 PH PH12020500201A patent/PH12020500201A1/en unknown
- 2020-01-28 ZA ZA2020/00561A patent/ZA202000561B/en unknown
- 2020-01-31 CL CL2020000283A patent/CL2020000283A1/es unknown
- 2020-02-11 CO CONC2020/0001469A patent/CO2020001469A2/es unknown
-
2021
- 2021-02-22 US US17/249,128 patent/US20220119369A1/en not_active Abandoned
- 2021-03-17 JP JP2021043173A patent/JP2021098751A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
US20220119369A1 (en) | 2022-04-21 |
AU2018312349A1 (en) | 2020-02-06 |
EA038912B1 (ru) | 2021-11-09 |
CO2020001469A2 (es) | 2020-05-29 |
CA3069990A1 (en) | 2019-02-07 |
JP2021098751A (ja) | 2021-07-01 |
US10968205B2 (en) | 2021-04-06 |
CN111032646B (zh) | 2023-01-03 |
JP7098716B2 (ja) | 2022-07-11 |
MA49570A (fr) | 2020-05-20 |
ZA202000561B (en) | 2022-04-28 |
US20190040043A1 (en) | 2019-02-07 |
WO2019027960A1 (en) | 2019-02-07 |
UA125318C2 (uk) | 2022-02-16 |
US20200216423A1 (en) | 2020-07-09 |
PH12020500201A1 (en) | 2020-10-12 |
IL272031A (en) | 2020-03-31 |
PE20201028A1 (es) | 2020-10-05 |
MY200629A (en) | 2024-01-06 |
SG11202000602YA (en) | 2020-02-27 |
CL2020000283A1 (es) | 2020-06-12 |
CN111032646A (zh) | 2020-04-17 |
BR112020002265A2 (pt) | 2020-07-28 |
JP2020529987A (ja) | 2020-10-15 |
EA202090413A1 (ru) | 2020-06-24 |
KR20200036004A (ko) | 2020-04-06 |
EP3652169A1 (en) | 2020-05-20 |
TW201920150A (zh) | 2019-06-01 |
US10538513B2 (en) | 2020-01-21 |
US10392368B2 (en) | 2019-08-27 |
US20190315724A1 (en) | 2019-10-17 |
AR112348A1 (es) | 2019-10-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12020500201A1 (en) | Pyrazolo and triazolo bicyclic compounds as jak kinase inhibitors | |
PH12017502050A1 (en) | Naphthyridine compounds as jak kinase inhibitors | |
MX2018013191A (es) | Compuestos de pirimidina como inhibidores de la quinasa jak. | |
PH12018502102A1 (en) | Pyrrolotriazine compounds as tam inhibitors | |
PH12019501985A1 (en) | Fused imidazo-piperidine jak inhibitors | |
PH12018500944A1 (en) | [1,2,4]TRIAZOLO[1,5-a]PYRIMIDIN-7-YL COMPOUND | |
MX2020003458A (es) | Derivados radiomarcados de un compuesto de 2-amino-6-fluoro-n-[ 5-fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3- carboxamida util como inhibidor de ataxia telangiectasia mutada y rad3 relacionado (atr) cinasa, preparacion de tal compuesto y diferentes formas solidas del mismo. | |
TW201613925A (en) | Imidazopyrazines as LSD1 inhibitors | |
MY195427A (en) | Jak Kinase Inhibitor Compounds for Treatment of Respiratory Disease | |
PH12020500528A1 (en) | Pyrimidine compound as jak kinase inhibitor | |
MX2016007371A (es) | Compuesto de 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]pirazolo[1, 5-a]pirimidin-3-carboxamida util como inhibidor de cinasa de ataxia telangiectasia mutada (atm) y rad3 relacionados (atr), su preparacion, diferentes formas solidas y sus derivados radiomarcados. | |
EA027213B9 (ru) | Соединения пиразолопиримидина в качестве ингибиторов киназ | |
MX2019005154A (es) | Derivados de [1,2,4]triazol[1,5-a]pirimidina como inhibidores de pde2. | |
MX2019005123A (es) | Compuestos de [1,2,4]triazolo[1,5-a]pirimidina como inhibidores de pde2. | |
MX2019005115A (es) | Compuestos de [1,2,4]triazolo[1,5-a]pirimidina como inhibidores de pde2. | |
PH12019500478A1 (en) | 8-(azetidin-1-yl)-[1,2,4]triazolo[1,5-a]pyridinyl compounds, compositions and methods of use thereof | |
PH12018500796A1 (en) | Cyclic ether derivatives of pyrazolo[1,5-a] pyrimidine-3-carboxamide | |
EA202192822A1 (ru) | Нафтиридиновые соединения в качестве ингибиторов jak киназы | |
MY192305A (en) | Bipyrazole derivatives as jak inhibitors |